Skip to main content
Glama

repurpose-mcp

An MCP server that helps rare disease clinicians and trial teams find approved drugs, probably off-patent, with a plausible mechanism for a disease. Every claim it makes is traceable to a public record: an Open Targets or ChEMBL ID, a ClinicalTrials.gov NCT number, or a PubMed PMID.

It is a hypothesis-generation tool for research teams, not a source of clinical advice.

Key finding

The pipeline mostly re-finds repurposing that has already been trialled. It almost never predicts it.

Recall@10 on 7 known repurposing cases

Result

Standard Open Targets association scores

4/7

With prior clinical evidence (clinical_precedence) removed

0/7

Standard scores include each drug's own trials for the disease, so the first number is partly circular. The second is closer to real prospective use, and it drops to zero.

The main reason is mechanistic. The tool only finds drugs that act directly on a disease-linked gene. Classic repurposing often works downstream. In LAM the disease gene is TSC2, but sirolimus acts on mTOR (via FKBP1A), a different protein further along the same pathway. Closing that gap, for example with one-hop pathway expansion, is the next step.

Cases are in evals/known_cases.csv, each checked against a primary source (trial registration, publication or regulatory approval). They cover five approved repurposings, one positive trial and one negative trial. Full results: evals/results.md.

Related MCP server: KnowS MCP Server

What it does

Ask Claude (Desktop or Code) for a repurposing brief on a disease. Claude then uses five tools that query public databases live:

Step

Tool

Source

What you get

1

find_disease

Open Targets Platform

Disease ID (MONDO/EFO/Orphanet) and name, with alternatives

2

disease_targets

Open Targets Platform

Genes/proteins most associated with the disease, with an overall score and a score per evidence type (genetics, somatic mutations, literature, animal models, prior clinical use…)

3

approved_drugs_for_targets

Open Targets + ChEMBL

Approved drugs acting on those targets: ChEMBL ID, mechanism of action, first approval year, approved indications, withdrawn flag, and a likely_off_patent heuristic

4

existing_trials

ClinicalTrials.gov API v2

Trials of the drug in the disease: NCT ID, title, phase, status, enrolment

5

literature

PubMed (NCBI E-utilities)

Articles mentioning both drug and disease: PMID, title, year, journal

The repurposing_brief prompt chains these together and asks Claude to produce one evidence table:

Drug

Target

Mechanism

Approval year

Off-patent heuristic

Trials

PMIDs

Evidence strength

Gaps

The prompt forbids uncited claims ("no claim without an ID") and invented identifiers. It also requires a grade for evidence strength (Strong / Moderate / Weak / Mechanistic only) based only on the records retrieved, and a stated reason for any downgrade.

Example output

Excerpt from a brief for lymphangioleiomyomatosis (LAM), produced 2026-11-17 with Open Targets data release 26.09 (full brief: evals/briefs/lymphangioleiomyomatosis.md):

Disease: lymphangioleiomyomatosis (MONDO_0011705) · Open Targets data 26.09

Drug

Target

Mechanism

Approval year

Off-patent heuristic

Trials

PMIDs

Evidence strength

Gaps

NINTEDANIB (CHEMBL502835)

PDGFRB (ENSG00000113721, 0.10); FGFR4, FLT4, FGFR2

PDGFR / VEGFR / FGFR inhibitor

2014 (ChEMBL)

unlikely (heuristic)

NCT03062943 (Ph2, completed, n=30)

PMID:39489895

Moderate

Downgraded from Strong: single-arm, open-label. No randomised comparison with sirolimus.

CELECOXIB (CHEMBL118)

PTGS2 (ENSG00000073756, 0.09)

Cyclooxygenase-2 inhibitor

1998 (ChEMBL)

likely (heuristic)

NCT02484664 (Ph2, completed, n=12)

PMID:32060062

Weak

12-participant pilot; the publication reports a phase I trial. Weak target association.

IMATINIB (CHEMBL941)

PDGFRB (0.10); ABL1 (0.09)

ABL / PDGFR-beta inhibitor

2001 (ChEMBL)

likely (heuristic)

NCT03131999 (Ph1/2, completed, n=18); NCT06889168 (Ph1, recruiting)

none found

Weak

Pilot with n<20; no published LAM results retrieved.

Already approved for this disease: SIROLIMUS (CHEMBL413). NCT00414648 (Ph3, n=89); PMID:31429781.

Limitations: read before using results

  • Not clinical advice. Output is a starting point for expert review, ethics and regulatory processes, not a treatment recommendation.

  • likely_off_patent is a heuristic. It is true when the first approval year is at least 20 years ago. It does not search patents. Formulation, method-of-use, paediatric and orphan exclusivities can outlast the compound patent. Old biologics may have no biosimilar. Generic availability differs by country. Verify in the FDA Orange Book (small molecules), Purple Book (biologics), or your national equivalent.

  • Approval year source. First approval year comes from ChEMBL first_approval (largely US FDA). When ChEMBL has no year, it falls back to the earliest regulatory approval in Open Targets (often EMA), which can understate a drug's age. The approval_year_source field says which was used.

  • Association scores are not efficacy evidence. An Open Targets score (0–1) summarises how much evidence links a gene to a disease. It says nothing about whether a drug acting on that gene helps patients. The "clinical" evidence type means drugs have already been trialled, so targets of already-tested drugs score higher.

  • Direct targets only. Drugs are found only if they act directly on an associated target. Drugs that act downstream of a disease gene are missed unless that target is itself associated. For example, sirolimus acts downstream of TSC2 loss in LAM. The recall eval shows how large this blind spot is (see below).

  • Searches are imperfect. ClinicalTrials.gov and PubMed expand synonyms, so results can include irrelevant records. For example, a "temsirolimus" trial search returns sirolimus trials. They can also miss relevant ones (non-English, unindexed, conference abstracts, unregistered trials). Read the titles.

  • Mechanism annotations are coarse. For example, tacrolimus and sirolimus share the ChEMBL "FKBP1A inhibitor" annotation but act on different downstream pathways.

  • Data freshness. Results reflect the live databases on the day you run them. Open Targets releases quarterly.

Install

You need uv and an internet connection. Then download or clone this folder, for example to C:\tools\repurpose_mcp or ~/tools/repurpose_mcp, and run uv sync inside it once.

An NCBI API key is optional but recommended: it raises PubMed's rate limit from 3 to 10 requests per second. You can get one free from your NCBI account settings. Set it as NCBI_API_KEY.

Claude Desktop

Open Settings → Developer → Edit Config and add the server to claude_desktop_config.json:

{
  "mcpServers": {
    "repurpose-mcp": {
      "command": "uv",
      "args": ["run", "--directory", "/ABSOLUTE/PATH/TO/repurpose_mcp", "python", "-m", "repurpose_mcp"],
      "env": { "NCBI_API_KEY": "optional-your-key" }
    }
  }
}

On Windows use a path like "C:\\tools\\repurpose_mcp". If Claude Desktop cannot find uv, put the full path to the uv executable in command (where uv on Windows, which uv on macOS). Restart Claude Desktop. To run the brief, click + → repurpose-mcp → repurposing_brief, enter the disease, and send.

Claude Code

claude mcp add repurpose-mcp -e NCBI_API_KEY=your-key -- uv run --directory /ABSOLUTE/PATH/TO/repurpose_mcp python -m repurpose_mcp

Then type /mcp__repurpose-mcp__repurposing_brief "Erdheim-Chester disease", or just ask, for example "find approved drugs that might be repurposed for Castleman disease, with sources".

The configs use python -m repurpose_mcp rather than the repurpose-mcp console script. Windows Smart App Control can block the unsigned launcher .exe that uv generates.

Evaluations

uv run python evals/run.py writes evals/results.md. It has two parts:

(a) Citation integrity. For each brief in evals/briefs/, every PMID and NCT ID is fetched and checked. A citation passes if the record exists and mentions both the drug of its table row (name, trade names or curated synonyms) and the disease (name or synonyms). To check your own brief, save Claude's output as a .md file in that folder, or run with --brief file.md. Passing means the record is real and on topic; it does not mean the record supports the claim made.

(b) Recall on known repurposing cases. For each case in evals/known_cases.csv, the eval checks whether the expected drug is in the top N candidates (default 10). Candidates are ranked by their best target association score. CSV columns:

disease,expected_drug,disease_id,expected_chembl_id,notes
lymphangioleiomyomatosis,sirolimus,MONDO_0011705,CHEMBL413,approved for LAM 2015

Only disease and expected_drug are required. Give disease_id to avoid mis-resolving the disease name, and expected_chembl_id for exact drug matching. Until you add your verified file, the eval uses evals/known_cases.example.csv (unverified examples) and says so in the results.

Recall runs twice. default uses standard Open Targets scores, which include the known repurposing's own trials, so the test is partly circular. no_clinical zero-weights that clinical evidence, which is closer to finding something new. On the example cases (2026-11-17), recall@10 was 4/7 by default and 0/7 with clinical evidence removed. In practice, the tool re-surfaces repurposing that is already in the clinical record much more reliably than it predicts new repurposing, mainly because of the direct-target limitation above.

Development

uv sync
uv run pytest                          # offline: replays recorded API responses (tests/cassettes)
REPURPOSE_RECORD=1 uv run pytest       # re-record against the live APIs

Engineering notes:

  • Requests use httpx with timeouts and up to four attempts, with exponential backoff and Retry-After support, on 429/5xx and network errors.

  • Rate limiting is per host: Open Targets and ChEMBL 5/s, ClinicalTrials.gov ~50/min, NCBI 3/s (10/s with a key).

  • A 6-hour in-memory cache serves repeat queries.

  • Tools return typed pydantic models, exposed as MCP structured output.

  • Schemas were checked against Open Targets API 26.9 and mcp 2.3.0 (where FastMCP is named MCPServer). Open Targets removed knownDrugs and yearOfFirstApproval: this server uses drugAndClinicalCandidates and the APPROVAL clinical stage, and takes approval years from ChEMBL.

Tool Schema Changelog

Recent tool additions, removals, and schema changes observed during successful MCP inspections.

Loading tool schema changelog…

    Related MCP Connectors

    Related MCP Servers